Search and Find

Book Title

Author/Publisher

Table of Contents

Show eBooks for my device only:

 

Cancer and Sexual Health

of: John P. Mulhall, Luca Incrocci, Irwin Goldstein, Ray Rosen

Humana Press, 2011

ISBN: 9781607619161 , 784 Pages

Format: PDF

Copy protection: DRM

Windows PC,Mac OSX,Windows PC,Mac OSX geeignet für alle DRM-fähigen eReader Apple iPad, Android Tablet PC's

Price: 255,73 EUR



More of the content

Cancer and Sexual Health


 

Preface

6

Contents

8

Contributors

12

Part I:Normal Sexual Function

20

Chapter 1: Functional Anatomy of the Male Sex Organs

21

Introduction

21

Penis

21

Skin and Fascia

21

Tunica Albigunea

22

Corpora Cavernosa and Spongiosum

23

Associated Musculature

24

Penile Vascular Anatomy (Fig. 1.2)

24

Lymphatics

26

Innervation

26

Urethra (Fig. 1.3)

26

Testis

27

Epididymis

28

Vas Deferens

28

The Prostate

29

Seminal Vesicles

29

References

29

Chapter 2: Functional Anatomy of the Female Sex Organs

31

Introduction

31

General Structural Relationships

31

External Genital Anatomy

32

Clitoris

32

Bulbs

34

Labia Majora

35

Labia Minora

35

Urethra

36

Blood Supply of the External Genitalia

37

Innervation of the External Genitalia

37

Internal Genital Anatomy

38

Vagina

38

Uterus

39

Uterine Corpus (or Body)

39

Cervix

40

Ovaries and Uterine Tubes

40

Blood Supply of the Internal Genitalia

40

Innervation of the Internal Genitalia (see Fig. 2.12)

40

References

41

Chapter 3: Physiology of Libido

42

Introduction

42

Sexual Arousal

42

Sexual Desire

45

Sexual Reward

46

Sexual Inhibition

47

Conclusions

47

References

48

Chapter 4: Physiology of Orgasm

51

Introduction

51

Definitions of Orgasm

51

Common Features of Orgasm in Males and Females

52

Mental Experience

52

Cardiovascular Phenomenon

52

Pelvic Musculature Contractions

52

Rectal Sphincter Contractions

53

Activation or Deactivation of Areas in the Brain

53

Facial Grimacing

53

Hyperventilation

54

Vocalizations

54

Release of Prolactin and Oxytocin

54

Differences Between Female and Male Orgasms

54

Female Orgasm

54

Uterine Contractions

55

Typologies of Female Orgasm

56

Female Orgasms with Urethral Emission

56

Objective Signs of Orgasm in Women

56

Specific Brain Activity During Female Orgasm

57

The Male Orgasm

57

The Male Orgasm with Ejaculation of semen

57

The Male Orgasm Without Ejaculation of Semen

57

The Post Ejaculatory Refractory Time (PERT)

58

Orgasms Induced by Prostatic Massage

58

Specific Brain Activity During Male Orgasms

58

Typology of Male Orgasms

59

Special Considerations

59

Can We Tell When Someone is Faking an Orgasm?

59

Orgasm and Enhancing its Intensity of Pleasure

59

Female Orgasm and Reproduction

60

Female Orgasm After the Menopause

60

Male Orgasm with Aging

61

Postorgasmic Illness Syndrome

61

Do Orgasms have Health Benefits Other than Pleasure?

61

Addendum

65

References

62

Chapter 5: Physiology of Female Genital Sexual Arousal

66

Introduction

66

Physiology

68

Central Factors in Female Sexual Arousal

68

Peripheral Factors in Female Sexual Arousal

69

Sex Steroid Hormones and Female Genital Sexual Arousal

69

Androgens: Physiology and Pathophysiology

70

Androgens: Clinical Data

71

Estrogens/Progestins: Physiology and Pathophysiology

72

Estrogens/Progestins: Clinical Data

73

Clinical Female Genital Sexual Arousal Disorder Syndrome Associated with Low Estradiol

73

Neurotransmitters and Female Genital Sexual Arousal

74

Vascular Blood Flow

75

Summary

76

References

76

Chapter 6: Physiology of Erection

84

Introduction

84

Neurological Regulation of Erectile Function

84

Cerebral Control of Penile Erection

84

Autonomic Control of Penile Erection

85

Somatic Nervous System and Penile Erection

85

Tissue Level Mechanisms of Penile Erection

85

Molecular Mechanisms of Penile Erection

86

Penile Detumescence

88

Tissue Level Mechanisms of Penile Detumescence

88

Neuronal Regulation of Penile Detumescence

88

Molecular Mechanisms of Penile Detumescence

88

Psychological Factors and Penile Detumescence

89

Endocrine Factors and Penile Erection

90

Conclusion

90

References

90

Chapter 7: Physiology of Ejaculation

92

Introduction

92

Peripheral Anatomical Organization

92

Organs Participating in Emission

93

Epididymis

93

Ductus (or Vas) Deferens

93

Seminal Vesicles

93

Prostate Gland

93

Bulbo-Urethral (or Cowper’s) Glands

93

Organs Participating in Expulsion

94

Bladder Neck and Urethra

94

Striated Muscles

94

Neural Pathways

94

Afferents

94

Efferents

94

Central Nervous System Network

96

Spinal Organization

96

Supraspinal Organization

96

Neurochemical Regulation

98

Dopaminergic Control

98

Serotonergic Control

99

Oxytocinergic Control

99

Human Brain Functioning

100

The Trigger for Expulsion

100

References

102

Part II:Disorders of Sexual Function

105

Chapter 8: Classifying Female Sexual Dysfunction

106

Introduction

106

Historical Overview of the Development of Classification of FSD

107

The DSM System

107

Definitions Reconsidering the DSM Definitions

108

The First Consensus Conference

108

Circular Model Versus a Linear Model and the Second Consensus Conference

108

DSM-V a Suggestion for New Definitions

112

DSM-V

112

Sexual Desire and Arousal Disorders

114

Sexual Aversion Disorder (SAD)

114

Female Orgasmic Disorder (FOD)

114

Dyspareunia

115

Conclusion

115

References

115

Chapter 9: Hypoactive Sexual Desire Disorder

117

Diagnosis

117

Theoretical Models of Sexual Desire

118

Assessment of HSDD (Table 9.2)

121

Differential Diagnosis

122

HSDD Prevalence in Epidemiological Studies

125

Factors Implicated with Sexual Desire

125

Biological Factors

125

Psychological Factors

126

Relationship

127

Cancer

127

Prevalence of Low Desire and HSDD in Cancer Patients

128

Direct Effects of Cancer on HSDD: Biological, Psychological, and Relational

128

Biological

128

Psychological Factors

128

Relational Factors

129

Effect of Cancer Treatment on HSDD

130

Chemotherapy

130

Radiation Therapy

130

Breast Conservation

131

Oophorectomy

131

Conclusions

132

References

133

Chapter 10: Disorders of Female Sexual Arousal

136

Disorders of Female Sexual Arousal

136

Definitions and Problems

137

Diagnostic Criteria for Female Sexual Arousal Disorder

137

Models of Sexual Response

137

Problems with the DSM conceptualization of FSAD

138

Proposed Criteria for the DSM-V

139

Epidemiology

139

Lifetime Prevalence of FSAD

139

Prevalence of FSAD in Cancer Patients

140

Correlates of FSAD

141

Physiological Correlates

141

Physiological Considerations for Cancer Patients

142

Psychological Correlates for FSAD

143

Psychological Considerations for Cancer Patients

143

FSAD in Partners of Patients

145

Assessment

145

Clinical Assessment of FSAD

146

Treatment Overview of FSAD

148

Biological Interventions

148

Topical Lubricants

148

Vasoactive Agents

149

Central Nervous System Acting Agents

149

Hormonal Agents

150

Psychological Interventions

150

Persistent Genital Arousal Disorder

151

Conclusion

152

References

153

Chapter 11: Disorders of Female Orgasm

158

Introduction

158

Definitions of Female Orgasm Disorder

158

The Prevalence of Female Orgasmic Disorder

159

The Impact of Cancer on Women’s Sexual Health

160

Effects of Specific Cancer Treatments on Orgasm Function

161

The Treatment of Female Orgasmic Disorder

162

Psychological Approaches (Table 11.1)

162

Directed Masturbation

162

Anxiety Reduction Techniques

165

Other Techniques

166

Pharmacological Approaches

166

Conclusion

170

References

170

Chapter 12: Sexual Pain Disorders

173

Introduction

173

Classification of Sexual Pain Disorders

173

Sexual Pain Disorders

175

Pain Related to a Specific Disorder

175

Vulvodynia

175

Epidemiology

176

Etiology

176

Psychosocial Factors

177

Assessment

178

Treatment

179

Dyspareunia in Postmenopausal Women

181

Vaginismus

182

Sexual Pain Disorders in Men

184

Dyspareunia and the Cancer Patient

184

Treatment-Related Side Effects

184

Treatment of Cancer-Related Sexual Pain

185

Summary

186

References

186

Chapter 13: Erectile Dysfunction: Prevalence and Pathophysiology

193

Introduction

193

Epidemiology of Erectile Dysfunction

193

Pathophysiology of Erectile Dysfunction

195

Overview

195

Ageing

195

Vascular Disease

197

Endocrine Factors

198

Neurological Factors

199

Conclusions

199

References

199

Chapter 14: Androgen Deficiency

204

Definition

204

Physiology of Hypothalamus-Pituitary-Gonadal Axis

204

Causes of Hypogonadism

206

Effects of Hypogonadism

208

Bone

208

Body Composition

209

Cognition and Mood

209

Metabolic Effects

209

Cardiovascular Effects

210

Sexual Function

211

Diagnosis of Hypogonadism

211

Treatment

212

Androgen Deficiency in the Female Patient

213

Physiology of Hypothalamic-Pituitary-Ovarian (HPO) Axis

213

Causes of Hypogonadism

214

Hypogonadotropic Hypogonadism

214

Eugonadotropic Hypogonadism

216

Hypergonadotropic Hypogonadism

216

Effects of Androgen Deficiency in Women

218

Diagnosis of Androgen Deficiency in Women

219

Treatment of Androgen Deficiency in Women

219

Conclusions

221

References

221

Chapter 15: Peyronie’s Disease

225

Definition

225

History

225

Etiology and Molecular Mechanisms

225

Evaluation of the PD Patient

226

Peyronie’s Disease Following Radical Prostatectomy

229

Nonsurgical Therapy for Peyronie’s Disease

229

Oral Therapies

231

L-Arginine

231

Pentoxifylline

231

Colchicine

231

Potassium Para-Aminobenzoate

232

Transdermal Agents

232

Intralesional Therapies

233

Steroids

233

Collagenase

233

Verapamil

233

Interferon

234

Penile Traction Devices

234

Surgical Treatment of Peyronie’s Disease

234

Tunica Albuginea Plication

235

Peyronie’s Plaque Incision/Partial Excision and Grafting

238

Straightening with Penile Prosthesis

240

References

240

Chapter 16: Disorders of Ejaculation and Male Orgasm

243

Introduction

243

The Anatomy and Physiology of the Ejaculatory Response

244

Premature Ejaculation

246

Introduction

246

Defining Premature Ejaculation

247

Epidemiology of Premature Ejaculation

250

Classification of Premature Ejaculation

250

The Aetiology of Premature Ejaculation

251

Premature Ejaculation and Performance Anxiety

252

Premature Ejaculation and Co-Morbid ED

253

Premature Ejaculation and Other Sexual Dysfunctions

253

Premature Ejaculation and Partner Sexual Dysfunction

253

Premature Ejaculation and Hyperthyroidism

254

Premature Ejaculation and Chronic Prostatitis

254

Delayed Ejaculation, Anejaculation, and Anorgasmia

255

Definition, Terminology, and Characteristics of Men with Delayed Ejaculation

255

Terminology and Definition

255

The Prevalence of Delayed Ejaculation and Characteristics of Men with DE

256

Pathophysiologies Commonly Leading to Ejaculatory Disorders, Including DE

257

Congenital Disorders

257

Traumatic Damage

257

Infective Disorders

257

Neurological Disorders

257

Male Pelvic Cancers

258

Prostate Cancer

258

Rectal Carcinoma

258

Testicular Cancer

259

Spinal Cord Injury

259

Psychological Aetiologies of Delayed Ejaculation

260

Conclusion

261

References

261

Chapter 17: Priapism

267

Background

267

Epidemiology of Priapism and Patient Populations at Risk

268

Diagnosis of Priapism

269

Pathophysiology of Priapism

271

Ischemic Priapism

271

Nonischemic Priapism

271

Stuttering Priapism

272

Medical Management

272

Surgical Management

276

Priapism and Cancer

282

References

284

Part III:Patient Assessment

287

Chapter 18: The Sexual Health Interview: Male

288

Introduction

288

Background Review

288

Helping Communication About Sex Between Patients and Physicians

290

Enhancing the Opportunity

291

Getting Started

292

Preparing the Patient

293

Taking a Sexual History from the Man

293

Erectile Function

294

General Comments

296

Conclusions

296

References

296

Chapter 19: The Sexual Health Interview: Female

298

Introduction

298

Epidemiology and Rationale

298

Sexual Problems in Women with Cancer

299

Need for Improved Sexual Health Dialogs

299

Patient Barriers to Sexual Health Dialogs

300

Physician Barriers to Sexual Health Discussions

300

Detection of Hypoactive Desire and Related Female Sexual Problems

300

Barriers to Sexual Health Dialogs in Female Cancer Patients

301

Physicians’ Desire for Sexual Health Education

301

Models for the Female Sexual Response

302

The Female Sexual Disorders: An Overview of Classification

303

Understanding Sexual Desire and its Components

303

Organizing a Biopsychosocial Approach to Sexual Dysfunction

303

The Three Windows Approach to Understanding Biopsychosocial Factors

304

Optimal Sexual History Taking

304

Screening and Detection of Sexual Problems

304

The Screening Sexual History

304

Screening with a “Ubiquity Statement”

305

The Screening Sexual History in Patients with Cancer

306

Developing the Narrative Thread

306

The Sexual Problem Interview

306

Language

307

Responding to Emotions

307

Using Patient-Centered Dialog to Explore Sexual Problems

308

Discussing Specific Sexual Practices

308

Essentials of a Complete Sexual History

309

Use of Questionnaires

309

Partner Issues

309

Empathic Delineation and Reframing Problems

310

The Interview as a Therapeutic Intervention

310

The P-LI-SS-IT Model

310

Conclusions

311

References

311

Chapter 20: Communication About Sexuality and Cancer

313

Introduction

313

Background Prevalence of Non-Communication

313

Who Should Communicate?

314

Barriers to Communication

314

Attitudes of Staff

314

Communicating with Patients

315

Communication with Partners

315

Communication with Families

316

Language Barriers

316

Communication with LGBT Individuals

317

Ethnicity

317

Disability

318

Barriers Related to Location

318

Clinician Education

319

Patient Information

319

Information to Public

320

Research

320

Conclusions

320

References

320

Chapter 21: Validated Questionnaires in Female Sexual Function Assessment

323

Introduction

323

Using Psychometrics to Evaluate an Instrument

323

Female Sexual Function Assessment Instruments (Tables 21.1–21.4)

324

Sexual Activity Questionnaire (SAQ)

324

Use in Cancer Populations

326

Sexual Function – Vaginal Changes Questionnaire (SVQ)

329

Use in Cancer Populations

329

The Female Sexual Function Index (FSFI)

329

Use in Cancer Populations

330

Derogatis Interview for Sexual Functioning (DISF/DISF-SR)

330

Use in Cancer Populations

331

Derogatis Sexual Functioning Inventory (DSFI)

331

Use in Cancer Populations

332

Brief Index of Sexual Functioning – Women (BISF-W)

332

Use in Cancer Populations

332

Changes in Sexual Functioning Questionnaire (CSFQ)

333

Use in Cancer Populations

333

Golombok-Rust Inventory of Sexual Satisfaction (GRISS)

334

Use in Cancer Populations

334

McCoy Female Sexuality Questionnaire (MSFQ)

334

Use in Cancer Populations

335

Other Measures of Female Sexual Functioning

335

Sexual Satisfaction Assessment Instruments

335

The Global Measure of Sexual Satisfaction (GMSEX)

336

The Index of Sexual Satisfaction (ISS)

337

The Pinney Sexual Satisfaction Inventory (PSSI)

337

The Female Sexual Distress Scale (FSDS)

337

The Sexual Satisfaction Scale for Women (SSS-W)

338

Summary

338

References

339

Chapter 22: Validated Questionnaires in Male Sexual Function Assessment

344

Introduction

344

Symptoms Scales and Questionnaires

344

Comprehensive Male Sexual Dysfunction Scales

345

Golombok Rust Inventory of Sexual Satisfaction

345

International Index of Erectile Function

346

Delayed Ejaculation Scales-Male Anorgasmia

346

Male Sexual Health Questionnaire

346

Premature Ejaculation Measures

347

Premature Ejaculation Profile

347

Index of Premature Ejaculation

347

Premature Ejaculation Diagnostic Tool

347

Treatment Satisfaction Scales

348

Treatment Satisfaction Scale

348

Erectile Dysfunction Inventory for Treatment and Satisfaction

348

Psychological and Interpersonal Relationship Scale

349

Sexual Quality of Life Scales

349

Sexual Life Quality Questionnaire

349

Self-Esteem and Relationship Questionnaire

349

Sexual Quality of Life: Male

350

Cancer-Specific Scales and Validation Data in Cancer Patients

350

Expanded Prostate Cancer Index Composite/UCLA Prostate Cancer Index

350

Validation of Scales in a Cancer Population

351

Summary and Conclusions

351

Appendix

351

Medical, Psychosocial, and Sexual Assessment Questionnaire

351

Erection

352

Libido/Interest

352

Ejaculation/Orgasm/Satisfaction

352

Satisfaction

352

Previous Consultations

352

References

353

Chapter 23: Evaluation of the Female with Sexual Dysfunction

355

Examination of the Female Cancer Patient

355

Specialized Testing for the Sexual Health Assessment

356

Laboratory Testing

356

Sonography

357

Advanced Testing

357

Vulvoscopy

357

Vaginal Photoplethysmography

357

Functional Magnetic Resonance Imaging

357

Quantitative Sensory Testing

358

Perinometry

358

Psychosexual Assessment After Cancer Diagnosis and Treatment

358

Surgical Considerations

358

Radiation Therapy Considerations

359

Chemotherapy Considerations

359

Hormone Therapy Considerations

359

Sexuality and Relationship Considerations

359

Other Psychological Considerations

359

Issues of Sexuality

360

Conclusions

360

References

360

Chapter 24: Evaluation of Male Sexual Dysfunction

361

Male Sexual Dysfunctions and Cancer Survivors

361

Changing Paradigms in the Evaluation of Erectile Dysfunction

362

Questionnaires and Sexual Function Symptom Scores

365

Questionnaires and Cancer Survivors

365

Medical, Sexual, and Psychosocial History

366

Medical History

366

Sexual History

367

Psychosexual History for the Nonmental Health Professional

368

Physical Examination

369

Laboratory Testing

369

Hormonal Evaluation

370

Cancer Survivors and Gonadal Status

371

Review of Findings

372

Specialist Consultation and Referral

372

Vascular Evaluations of Erectile Dysfunction

374

First-Line Evaluation of Penile Blood Flow

374

Second-Line Evaluations of Penile Blood Flow

374

Penile Doppler Sonography

374

Recommendations of the ICSM on Penile Vascular Testing

377

Selective Internal Pudendal Arteriography

377

Nocturnal Penile Tumescence

379

Hypoactive Sexual Desire

379

Ejaculatory Disorders

380

Cancer Survivors and Ejaculatory Dysfunction

381

Specific Ejaculatory Dysfunctions

382

Conclusions

383

References

383

Chapter 25: The Impact of Cancer on the Partner’s Sexuality

387

Introduction

387

What is Sexuality? Concepts of Human Sexuality

387

Human Sexuality from a Systems Perspective: The Four Component Sexual Model

388

The Impact of Cancer on Sexuality from a Systems Perspective

389

Impact of Cancer on the Partner’s Sexuality from a Systems Perspective

390

Impact of Male Sexual Dysfunction on Partners

392

Impact of Female Sexual Dysfunction on Male Partners

394

Impact of Cancer Diagnosis and Treatment on the Partner’s Sexuality

394

Psychological Impact of Cancer on Partner

394

Sexual and Intimacy Effects of Cancer on the Partner

395

Psychosocial Impact on the Partner of Men with Prostate Cancer

396

Impact on the Partner of Women with Breast Cancer

397

Clinical Intervention of Health Care Professionals

397

Conclusion

398

References

398

Chapter 26: Gay and Lesbian Patients with Cancer

400

Introduction

400

Health Care Provider Assumptions

400

Special Considerations for Lesbians

401

Special Considerations for Gay Men

401

Prostate Cancer

401

Colorectal Cancer

402

Attitudes of Health Care Providers to Gay/Lesbian Patients

402

Homophobia

402

Heterosexism

403

Disclosure of Same Sex Attraction or Relationship

403

How Oncology Care Providers Can Help

404

PLISSIT Model

404

Conclusion

405

References

405

Part IV:Cancer and Sex

407

Chapter 27: The Impact of a Cancer Diagnosis on Sexual Health

408

Introduction

408

The Psychological Response to a Cancer Diagnosis and Its Impact on Sexual Functioning

409

Partners Perception of Diagnosis and Affects on Sexuality (Table 27.2)

410

The Lack of Discussion of Sexuality at Diagnosis (Table 27.3)

412

Conclusion

414

References

414

Chapter 28: Breast Cancer

416

Breast Cancer Epidemiology and Population Data on Sexuality

416

The Interactive Biopsychosocial Model Applied to Sexualityand Breast Cancer

418

Sexuality and the Breast Cancer Care Continuum

420

Breast Cancer Risk Factors and Sexuality

420

Breast Cancer Screeningand Sexuality

421

Average-Risk Women Screening Guidelines

421

Very High-Risk Women Screening Guidelines

421

Diagnosis

425

Treatment

426

Surgery

426

Chemotherapy

429

Adjuvant Chemotherapy

431

Taxanes

431

Trastuzumab/Herceptin

436

Radiation

436

Hormonal Therapy: Pre- and Perimenopausal Women

436

Aromatase Inhibitors

438

Zoledronic Acid

438

Adjuvant Hormonal Therapy: Postmenopausal Women

439

Targeted Palliative Therapies

439

Bevacizumab

440

Lapatinib

440

Complications from Cancer Therapy

440

Treatment of Sexual Problems in Breast Cancer Survivors

441

Vaginal Dryness

441

Pain with Intercourse

443

Vaginal Stenosis

445

Vaginismus

446

Low or Absent Sexual Desire and Difficulty with Arousal and Orgasm

447

Role of Psychotherapy, Sex Therapy, Couples and Marital Therapy, Psychiatric Medications

448

Cancer Survivorship and Health Maintenance

450

Bone Health

450

Cardiovascular Health

451

Key Research Questions and Needs to Advance Care of Sexuality Issues in People with Breast Cancer or Elevated Breast Cancer Risk

451

References

451

Chapter 29: Gynecological Cancers

457

General Considerations

457

The Etiopathogenetic Framework of Sexual Dysfunction in Genital Cancer Patients

458

Cancer of the Vulva

458

Impact of the Disease and Treatment Procedures

458

Prevalence and Incidence of Sexual Dysfunction and Contributing Factors

458

Cancer of the Vagina

459

Impact of the Disease and Treatment

459

Prevalence, Incidence of Sexual Dysfunction, and Contributing Factors

459

Cancer of the Cervix

459

Impact of the Disease and Treatment

459

Prevalence, Incidence of Sexual Dysfunction, and Contributing Factors

460

Quality of Life Studies

460

Differences Between Treatment Procedures (Table 29.1)

460

Specific Physical Findings and Sexual Dysfunction (Table 29.2)

462

Contributing Factors

464

Endometrium Carcinoma

466

Impact of the Disease and Treatment

466

Prevalence, Incidence of Sexual Dysfunction, and Contributing Factors

466

Cancer of the Ovaries

467

The Impact of the Disease and Treatment

467

Prevalence, Incidence of Sexual Dysfunction, and Contributing Factors

467

Assessment of Sexual Functioning

468

Therapy

468

Psychological Interventions

469

Local Nonhormonal and Mechanical Interventions

470

Lubricants

470

Vaginal Dilatation

471

Hormonal

471

Local Estrogen

471

Summary and Conclusion

472

References

473

Chapter 30: Pelvic Surgery for Urological Cancers

476

Anatomy of Erectile Function

476

Arterial Supply

476

Accessory Pudendal Arteries

476

Venous Drainage

477

Neuroanatomy

477

Corporal Smooth Muscle

478

Erectile Dysfunction Prevalence

478

Erectile Dysfunction Pathophysiology

479

Neural Trauma

479

Corporal Smooth Muscle Alterations

480

Venous Leak

481

Radical Prostatectomy-Associated Sexual Dysfunctions

481

Anejaculation

481

Orgasm Alterations

481

Peyronie’s Disease

482

Penile Length Alterations

483

References

484

Chapter 31: Pelvic Radiation in Men

488

Introduction

488

Methods for the Evaluation of Erectile Dysfunction

488

Definition of Potency

488

Etiology of Postradiation Erectile Dysfunction

489

Incidence of Erectile Dysfunction After Radiotherapy for Prostate Cancer

489

Incidence of Erectile Dysfunction After External-Beam Radiotherapy

489

Incidence of Erectile Dysfunction After Brachytherapy

489

Incidence of Erectile Dysfunction After Radiotherapy for Bladder Cancer

492

Incidence of Erectile Dysfunction After Radiotherapy for Penile Cancer

493

Incidence of Erectile Dysfunction After Radiotherapy for Testicular Cancer

494

Incidence of Erectile Dysfunction After Radiotherapy for Colorectal Cancer

496

Ejaculatory and Other Sexual Dysfunctions

497

Therapy of Postradiation Erectile Dysfunction

497

Prevention of Postradiation Erectile Dysfunction

497

Conclusion

498

References

498

Chapter 32: Pelvic Radiation in Women

502

Radiotherapy for Cancer in the Pelvis

502

Late Effects of Radiotherapy

503

Assessment of Sexual Function

505

Psycho-sexual Effects of Pelvic Radiation

506

Sexual Problems After Pelvic Radiation

507

Gynaecological Cancer

507

Rectal Cancer

512

Anal Cancer

514

Bladder Cancer

515

Intervention for Female Sexual Dysfunction

516

Premature Ovarian Failure

516

Hormone Replacement Therapy

516

Post-irradiation Vaginitis/Vaginal Mucositis

516

Oestrogen

516

Benzydamine

517

Hyperbaric Oxygen Therapy

517

Vaginal Dilators

517

Conclusion

518

References

518

Chapter 33: Impact of Chemotherapy and Hormone Therapy on Female Sexual Health

524

Introduction

524

Impact of Chemotherapy on Female Sexual Health

525

Impact of Hormone Therapy on Female Sexual Health

527

Management Strategies for Female Sexual Symptoms Related to Chemotherapy and Hormone Therapy

528

References

530

Chapter 34: Impact of Androgen Deprivation Therapy on Men’s Sexual Health

534

Introduction

534

Role of Testosterone on Male Sexual Health

535

Physiology of Testosterone

536

Hypothalamus-Pituitary-Testis Axis

536

Production of Androgens by the Adrenal Gland

536

Mechanism of Action of Androgen Deprivation Therapy

537

Medical Castration

537

Surgical Castration

538

Antiandrogens

538

Inhibition of Androgen Synthesis

538

Androgen Deprivation Therapy Effects on Sexual Function

538

Erectile Function

539

Ejaculation

540

Libido

540

Genital Changes

541

Assessment of Patients on Androgen Deprivation Therapy

541

Therapeutic Strategies for Patients on Androgen Deprivation Therapy

542

Intermittent Versus Continuous Androgen Deprivation Therapy

542

Penile Rehabilitation

543

Conclusions

543

References

543

Chapter 35: Colorectal Cancer

547

Overview of Treatment of Colon and Rectal Cancer

547

The Impact of Colorectal Cancer Diagnosis on Psycho-Sexual Functioning

548

The Impact of a Stoma on Sexual Functioning

549

The Impact of Treatment of Rectal Cancer on Male Sexual Functioning (Table 35.1)

550

The Impact of Treatment of Rectal Cancer on Female Sexual Function

553

Counseling and Treatment

555

References

556

Chapter 36: Stem Cell Transplant

559

Description of HSCT

559

Challenges from the Start of HSCT

560

Challenges After HSCT

560

Treatment Factors Contributing to Sexual Dysfunction

561

Chemotherapy and TBI

561

Graft Versus Host Disease and Sexuality

562

The Interaction of Physiological, Behavioral, Psychological, and Social Effects on Sexuality After HSCT

562

Other Issues Contributing to Sexual Function

563

Psychological Factors Contributing to Sexual Dysfunction

563

Determining Who Is at Greater Risk for Sexual Dysfunction After HSCT

564

Evaluating Sexual Functioning After HSCT

565

Medical Treatment Options

566

Behavioral Treatment Options

568

Research Needs in the HSCT Population

570

Conclusions

570

References

570

Chapter 37: Sexual Health in the Terminally III

574

Introduction

574

Sexuality and Intimacy in Cancer and Palliative Care

574

Experiencing a Cancer Diagnosis

574

Effects of Cancer Treatment on Sexuality and Intimacy

575

Treatment Ends: Now What?

575

Sexuality in the Palliative or Terminal Settings

575

Discussing Patient Sexuality in Palliative and Terminal Care

576

The Why of Sex

577

The Direct Physical Benefits of Sexual Expression

577

The How of Sex in the Palliative Stage?

578

Various Reactions and Topics in the Palliative–Terminal Phase

578

The Role of the Medical and Helping Professionals

579

Various Organizational Problems and Solutions

579

Introducing Discussions About Patient Sexuality and Intimacy

579

Creating Space/Room for Undisturbed Intimacy

580

Various Physical Problems and Solutions

580

Conclusions

583

References

583

Part V:Treatment Strategies

585

Chapter 38: Survivorship: An Overview

586

Introduction

586

Definition of Survivorship

586

Current Focus on Survivorship

587

A National Survivorship Agenda

587

Challenges of Survivorship

587

Models of Survivorship Care

589

Current and Evolving Clinic Models

589

Providing a Care Plan for Survivorship

590

Cancer and Sexuality: Where Does Survivorship Fit In

592

Oncology Clinician Practice Related to Sexual Health

592

Sexual Health as an Exemplar for Survivorship Care

593

Improving Clinical Practice

593

Institutional Program Development

593

National Advocacy

594

References

594

Chapter 39: Nutriceuticals in Sexual Health

597

Introduction (Part 1): Heart Health=Sexual Health (Ageless Education)

597

Introduction (Part 2): Heart Health=Sexual Health and Promoting Probability

598

Conclusion

614

References

615

Chapter 40: Medical Treatments for Sexual Problems in Women

621

Introduction

621

Iatrogenic Menopause

621

Fertility Preservation

622

Embryo Cryopreservation

622

Cryopreservation of Mature Oocytes

622

Cryopreservation of Immature Oocytes After In Vitro Maturation (Without Gonadotropin Stimulation)

623

Gonadotropin-Releasing Hormone Analogue Treatment

623

Cryopreservation of Ovarian Tissue

623

Medical Therapies of Sexual Disorders in Cancer Survivors

623

Hormone Therapy

625

Systemic

625

Estrogens

626

Estrogen and Progestins

626

Estrogen/Androgen Combination Therapy

626

Transdermal Testosterone Specifically for Women

627

Synthetic Steroids

627

Topical Hormonal Therapies

628

Nonhormonal Central Nervous System Acting Drugs

628

Antidepressants in Sexual Problems and Depression

628

Bupropion

628

Synergy Between Antidepressants and HRT in Addressing Sexual Disorders

629

Antidepressant Drugs in the Treatment of Menopausal and Sexual Symptoms

630

Nonhormonal Topical Treatments

630

Vasoactive Agents in Women

630

Botulin Toxin

630

Future Treatment Options

631

Flibanserin

631

Psychosocial Interventions

632

Conclusion

632

References

633

Chapter 41: Surgical Treatments for Sexual Problems in Women

636

Introduction

636

Vulvar Anatomy

636

Terminology

637

Vestibulodynia

637

Clitoral Phimosis

638

Perineoplasty

638

Bartholin’s Gland

639

Conclusions

639

References

640

Chapter 42: Sex Therapy in Female Sexual Dysfunction

641

Introduction

641

Gender Differences withSexual Function After Cancerand Physician Impact withPatient Response

641

Clinical Considerations for Diagnosis and Treatment of Women with Genital and Breast Cancer

642

Psychosocial Implicationsof Cancer on Women and Their Sexual Function

643

Mental Health Interventions (Table 42.1)

644

Support Groups

644

Hypnotherapy

644

Psychotherapy

644

Cultural Differences in Sexual Functioning for Women with Cancer

646

References

647

Chapter 43: Erectile Function Preservation for Men with Cancer

649

Introduction

649

Erectile Tissue Structure and Function

650

Cancer Treatments and Erectile Tissue Damage

650

Pelvic Surgery

650

Pelvic Radiation

652

Androgen Deprivation Therapy

652

Erectile Tissue Damage and Erectile Dysfunction

653

Erectile Tissue Preservation and Cancer Treatments

655

Erectile Tissue Preservation: Animal Study Data (Table 43.1)

656

Erectile Tissue Preservation: Human Study Data (Table 43.2)

659

Summary

662

References

663

Chapter 44: Erectile Dysfunction: Pharmacological Therapy

666

Introduction

666

Historical Review of Modern Erectile Dysfunction Pharmacotherapy

666

Goals of Pharmacological Therapy

667

Oral Agents

669

Phosphodiesterase 5 Inhibitors

669

Sildenafil

669

Tadalafil

673

Vardenafil

674

Nonarteritic Ischemic Optic Neuropathy

675

Sudden Sensorineural Hearing Loss

675

PDE5 Inhibitors Failures

675

Dopamine Receptor Agonists

676

Apomorphine

676

Adrenergic Receptor Antagonists

676

Yohimbine

676

Phentolamine

677

Serotonergic Receptor Agonists

677

Trazodone

677

Other Oral Agents

677

Transdermal Agents

677

Intracavernosal Agents

677

Alpha-Adrenoreceptor Blocking Agents

678

Phentolamine

678

Phosphodiesterase Inhibitor

678

Papaverine

678

Adenylate Cyclase Activators

678

Alprostadil (Prostaglandin E 1)

678

Other Intracavernosal Agents

679

Intracavernosal Agent Combinations

679

Important Aspects of Intracavernous Injection Therapy

680

Transurethral Therapy

681

References

682

Chapter 45: Erectile Dysfunction: Devices

688

Introduction

688

Vacuum Erection Devices

688

Penile Implants

691

Noninflatable Penile Implants

692

Inflatable Penile Implants

694

Conclusion

697

References

697

Chapter 46: The Management of Premature Ejaculation

699

Introduction

699

History of Premature Ejaculation

699

Definition of Premature Ejaculation (Table 46.1)

699

Research of Definition

700

Animal Model of Premature Ejaculation

701

Normal and Abnormal Ejaculation Time

701

Classification of Premature Ejaculation

701

Lifelong Premature Ejaculation

701

Acquired Premature Ejaculation

702

Two New Subtypes of Premature Ejaculation

702

Natural Variable Premature Ejaculation

702

Premature-Like Ejaculatory Dysfunction

703

Genetics of Lifelong Premature Ejaculation

703

Drug Treatment of Premature Ejaculation (Table 46.2)

703

Daily Oral Medication

704

On-Demand Drug Treatment

705

SSRIs

705

Dapoxetine

705

Tramadol

705

PDE5 Inhibitors

706

Topical Anesthetics

706

Inadequate Intracavernous Self-Injection Therapy for PE

706

Psychologic Treatment of Premature Ejaculation

706

Psychotherapy

706

Stop-Start Method

707

The Squeeze Technique

707

Sensate Focus

707

Clinical Interview of Men with Complaints of Premature Ejaculation

707

Relevant Questions for Considering Different Treatment Options

708

Summary

708

References

709

Chapter 47: Testosterone Therapy in the Male Cancer Patient

711

Overview

711

Introduction

712

Testosterone Deficiency and the Prostate Cancer Patient

712

The Origin of the Prohibition Against TTh in Prostate Cancer Patients

712

Historical Experience with Testosterone and Prostate Cancer

713

The Original Report: Huggins and Hodges

713

Historical Experience with T Administration in Men with PCa

713

The Memorial-Sloan Kettering Experience

714

Modern Evidence Regarding Testosterone and the Risk of PCa

714

Natural History

714

Longitudinal Studies of Serum Testosterone and Subsequent Risk of Prostate Cancer

714

Clinical TTh Trials

715

TTh in Men with Prostatic Intraepithelial Neoplasia

715

Prostate Biopsy in Men with Low Testosterone

715

Testosterone Flare and PSA

715

Testosterone Treatment in Men with Prostate Cancer

716

Rationale

716

Testosterone Following Radical Prostatectomy

716

Testosterone Following Other Treatments for PCa

717

TTh in Men with Untreated or Recurrent PCa

717

Current Understanding of the Relationship of PCa and T

717

Conclusions

718

References

718

Chapter 48: Sex Therapy in Male Sexual Dysfunction

721

Introduction

721

Psychological and Sexual Impact on Men and Their Partners

722

The Men

722

The Partners

722

The Relationship

723

Psychosocial Interventions

723

Role of Sex Therapy and Psychotherapy

724

Review of Existing Psychosocial Programs

724

Other Suggestions Regarding Content and Timing of Interventions

725

Conclusion

726

References

727

Chapter 49: Restoring Intimacy in Relationships Affected by Cancer

729

Introduction

729

Prostate Cancer, Intimacy, and the Marital Relationship

729

Psychosocial Interventions Addressing Relationship Intimacy Needs

732

Patient-Focused Psychological Interventions

733

Partner-Focused Psychological Interventions

734

Couple-Focused Psychological Interventions

735

Future Directions

737

Conclusion

738

References

738

Chapter 50: Dating and Disclosure for Cancer Survivors

741

Introduction

741

Theoretical Perspectives on Disclosure

742

Dating and Disclosure in the Context of Cancer

743

Culture as Context

745

Age and Developmental Stage

745

Gender

746

Race/Ethnicity, Socioeconomic Status, and Religion

746

Sexual Orientation and Gender Identity

747

Patient Information and Resources

747

Clinical and Research Implications

749

Conclusion

750

References

751

Index

753